Goldman Sachs Group Inc. Acquires 772,829 Shares of Haleon plc (NYSE:HLN)

Goldman Sachs Group Inc. grew its holdings in Haleon plc (NYSE:HLN) by 19.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,813,997 shares of the company’s stock after acquiring an additional 772,829 shares during the period. Goldman Sachs Group Inc. owned 0.10% of Haleon worth $39,619,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Blue Barn Wealth LLC boosted its position in Haleon by 7.3% during the fourth quarter. Blue Barn Wealth LLC now owns 20,858 shares of the company’s stock worth $172,000 after purchasing an additional 1,425 shares during the period. Baker Tilly Wealth Management LLC grew its stake in Haleon by 6.1% in the 4th quarter. Baker Tilly Wealth Management LLC now owns 32,989 shares of the company’s stock valued at $271,000 after buying an additional 1,905 shares during the last quarter. CWM LLC grew its stake in Haleon by 13.1% in the 4th quarter. CWM LLC now owns 18,606 shares of the company’s stock valued at $153,000 after buying an additional 2,156 shares during the last quarter. Axxcess Wealth Management LLC raised its holdings in Haleon by 12.9% in the 4th quarter. Axxcess Wealth Management LLC now owns 18,836 shares of the company’s stock worth $155,000 after acquiring an additional 2,156 shares during the period. Finally, Hexagon Capital Partners LLC grew its position in shares of Haleon by 107.3% in the fourth quarter. Hexagon Capital Partners LLC now owns 4,236 shares of the company’s stock valued at $35,000 after purchasing an additional 2,193 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Trading Up 0.7 %

Shares of HLN opened at $8.58 on Friday. The company has a current ratio of 1.04, a quick ratio of 0.73 and a debt-to-equity ratio of 0.53. The stock has a market cap of $39.18 billion, a PE ratio of 28.60, a PEG ratio of 2.25 and a beta of 0.26. Haleon plc has a 1 year low of $7.70 and a 1 year high of $8.96. The stock has a 50 day simple moving average of $8.38 and a 200-day simple moving average of $8.33.

Haleon (NYSE:HLN) last announced its earnings results on Wednesday, May 1st. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. Haleon had a net margin of 9.68% and a return on equity of 13.17%. The business had revenue of $3.70 billion during the quarter, compared to analysts’ expectations of $3.71 billion. On average, sell-side analysts predict that Haleon plc will post 0.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HLN has been the subject of several research reports. HSBC started coverage on shares of Haleon in a research note on Wednesday, April 17th. They issued a “buy” rating for the company. Berenberg Bank began coverage on shares of Haleon in a research note on Wednesday, June 5th. They set a “buy” rating on the stock. Finally, Argus restated a “buy” rating on shares of Haleon in a research note on Tuesday, March 26th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.